-
EP1638574
European procedure
Extract from the Register of European Patents
EP About this file: EP1638574
| EP1638574 - NEW PHARMACEUTICAL USES OF STAUROSPORINE DERIVATIVES [Right-click to bookmark this link] | Status | No opposition filed within time limit Status updated on 18.02.2011 Database last updated on 08.04.2026 | Most recent event Tooltip | 18.02.2011 | No opposition filed within time limit | published on 23.03.2011 [2011/12] | Applicant(s) | For:BE
BG
CH
CY
CZ
DE
DK
EE
ES
FI
FR
GB
GR
HU
IE
IT
LI
LU
MC
NL
PL
PT
RO
SE
SI
SK
TR
Novartis AG Lichtstrasse 35 4056 Basel / CH | For:AT
Novartis Pharma GmbH Brunner Strasse 59 1230 Wien / AT | [2010/15] |
| Former [2009/43] | For:BE
BG
CH
CY
CZ
DE
DK
EE
ES
FI
FR
GB
GR
HU
IE
IT
LI
LU
MC
NL
PL
PT
RO
SE
SI
SK
TR
Novartis AG Lichtstrasse 35 4056 Basel / CH | ||
| For:AT
Novartis Pharma GmbH Brunner Strasse 59 1230 Wien / AT | |||
| Former [2006/29] | For:BE
BG
CH
CY
CZ
DE
DK
EE
ES
FI
FR
GB
GR
HU
IE
IT
LI
LU
MC
NL
PL
PT
RO
SE
SI
SK
TR
Novartis AG Lichtstrasse 35 4056 Basel / CH | ||
| For:AT
Novartis Pharma GmbH Brunner Strasse 59 1235 Vienna / AT | |||
| Former [2006/13] | For:BE
BG
CH
CY
CZ
DE
DK
EE
ES
FI
FR
GB
GR
HU
IE
IT
LU
MC
NL
PL
PT
RO
SE
SI
SK
TR
Novartis AG Lichtstrasse 35 4056 Basel / CH | ||
| For:AT
Novartis Pharma GmbH Brunner Strasse 59 1235 Vienna / AT | Inventor(s) | 01 /
COUTRE, Steven 703 Welch Road, G-1 Stanford, CA 94305 / US | [2006/13] | Representative(s) | Roth, Peter Richard Novartis AG Corporate Intellectual Property 4002 Basel / CH | [N/P] |
| Former [2006/13] | Roth, Peter Richard Novartis AG Corporate Intellectual Property 4002 Basel / CH | Application number, filing date | 04740016.3 | 17.06.2004 | [2006/13] | WO2004EP06562 | Priority number, date | US20030479575P | 18.06.2003 Original published format: US 479575 P | [2006/13] | Filing language | EN | Procedural language | EN | Publication | Type: | A2 Application without search report | No.: | WO2004112794 | Date: | 29.12.2004 | Language: | EN | [2004/53] | Type: | A2 Application without search report | No.: | EP1638574 | Date: | 29.03.2006 | Language: | EN | The application published by WIPO in one of the EPO official languages on 29.12.2004 takes the place of the publication of the European patent application. | [2006/13] | Type: | B1 Patent specification | No.: | EP1638574 | Date: | 14.04.2010 | Language: | EN | [2010/15] | Search report(s) | International search report - published on: | EP | 16.06.2005 | Classification | IPC: | A61K31/553, A61P37/08, A61P27/14 | [2006/13] | CPC: |
C07D498/16 (EP,US);
A61K31/553 (EP,US);
A61P11/00 (EP);
A61P11/02 (EP);
A61P17/00 (EP);
A61P17/04 (EP);
A61P25/00 (EP);
A61P27/00 (EP);
A61P27/14 (EP);
A61P27/16 (EP);
A61P3/04 (EP);
A61P31/10 (EP);
A61P35/00 (EP);
A61P37/00 (EP);
A61P37/08 (EP);
| Designated contracting states | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR [2006/13] | Extension states | AL | Not yet paid | HR | Not yet paid | LT | Not yet paid | LV | Not yet paid | MK | Not yet paid | Title | German: | NEUE PHARMAZEUTISCHE VERWENDUNGEN VON STAUROSPORIN-DERIVATEN | [2006/13] | English: | NEW PHARMACEUTICAL USES OF STAUROSPORINE DERIVATIVES | [2006/13] | French: | NOUVELLE UTILISATION DE DERIVES DE STAUROSPORINE | [2006/13] | Entry into regional phase | 18.01.2006 | National basic fee paid | 18.01.2006 | Designation fee(s) paid | 18.01.2006 | Examination fee paid | Examination procedure | 21.03.2005 | Request for preliminary examination filed International Preliminary Examining Authority: EP | 18.01.2006 | Examination requested [2006/13] | 11.11.2008 | Despatch of a communication from the examining division (Time limit: M06) | 20.05.2009 | Reply to a communication from the examining division | 04.06.2009 | Despatch of a communication from the examining division (Time limit: M02) | 14.08.2009 | Reply to a communication from the examining division | 04.11.2009 | Communication of intention to grant the patent | 10.02.2010 | Fee for grant paid | 10.02.2010 | Fee for publishing/printing paid | Opposition(s) | 17.01.2011 | No opposition filed within time limit [2011/12] | Fees paid | Renewal fee | 30.06.2006 | Renewal fee patent year 03 | 02.07.2007 | Renewal fee patent year 04 | 28.03.2008 | Renewal fee patent year 05 | 16.06.2009 | Renewal fee patent year 06 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [X] WO9749406 (CEPHALON INC et al.) [X] 1,2,6 * claims 2,5 * | [PX] WO03065995 (SUPERGEN INC et al.) [PX] 1,2,4,6 * claims 33,35,45,53 * | [X] WO9962537 (UNIV ROCKEFELLER et al.) [X] 1,2,6 * page 5, lines 7-9; claims 12,16,18,26 * | [A] WO9848795 (LILLY CO ELI et al.) [A] 1 * page 3, lines 21,22; claim - * | [A] JPS63295589 | [A] WO0246197 (ORTHO MCNEIL PHARM INC et al.) [A] 1 * claims 13-17,31,32 * | [A] EP0470490 (HOFFMANN LA ROCHE et al.) [A] 1,2 * page 6, line 55; claim 1 * | [X] WO03037347 (NOVARTIS AG et al.) [X] 10 * claim - * | [A] WO02080925 (NOVARTIS AG et al.) [A] 1-19 * See claim 1: treatment of infant death syndrome, bronchopulmonary aspergillosis, mastocytosis, multiple sclerosis.;; claims 4,5 * | [A] US4639455 (MOORE LUANA et al.) [A] 1-3,6,8,11,19 * See claim 1: prevention of sudden infant death syndrome * | [A] EP0518468 (NEURIM PHARMA 1991 et al.) [A] 1-3,6,8,11,19 * claim 6 * * See claim 6: prevention of sudden infant death syndrome. * | [A] WO9631514 (SANDOZ LTD et al.) [A] 1-3,6,8,10,11,13-19 * See treatment of bronchopulmonary aspergillosis: page 15, line 6;; claim 1 * | [E] WO2004091663 (KYOWA HAKKO KOGYO KK et al.) | [E] WO2004093910 (FUJISAWA PHARMACEUTICAL CO et al.) | [Y] WO9957117 (ASTA MEDICA AG et al.) [Y] 1,4-7,19 * See formula (XV) at page 58 and see compounds having RN: 249763-04-0 249763-08-4 * * page 2, paragraph 3 * * claims 20,21 * | [Y] EP0370236 (GOEDECKE AG et al.) [Y] 1,4-7,19 * See compounds of formula I and II and see compounds having RN: 129514-14-3, 129514-15-4, 129514-16-5, 129514-17-6, 129514-18-7, 129514-19-8, 129514-20-1, 129514-38-1, 129514-39-2, 129532-86-1 * * See claim 4: treatment of allergies and inflammatory conditions, and neurodegenerative disorders * | [Y] EP0434057 (GOEDECKE AG et al.) [Y] 1,4-7,19 * See compounds of formula (I) and (II) * * See claim 10: treatment of allergies, bronchopulmonary disorders, neurodegenerative disorders * | [DY] EP0384349 (HOFFMANN LA ROCHE et al.) [DY] 1,4-7,19 * See compounds of formula (I) and (II) * * See claims 20-21: treatment inflammatory disorders, bronchopulmonary disorders, asthma, immune disorders. * | [Y] EP0397060 (GOEDECKE AG et al.) [Y] 1,4-7,19 * See compounds of formula (I), (VII), (VIII) * * See claims 7 and 8: treatment of inflammations, allergies, degenereative diseases of the CNS. * | [Y] US6284783 (ZHOU TONG et al.) [Y] 1,4-7,19 * See compounds of formula (I) * * claim - * | [DY] EP0328026 (HOFFMANN LA ROCHE et al.) [DY] 1,4-7,19 * See compounds of formula (I), (II), and see examples. * * See claim 12: treatment of inflammatory, immunological and brunchopulmonary disorders. * | [DY] EP0624586 (HOFFMANN LA ROCHE et al.) [DY] 1,4-7,19 * See compounds of formula (I) and (II) and see examples * * See claims 12 and 13: treatment of inflammatory disorders, immunological disorders, asthma, bronchopulmonary disorders * | [A] DATABASE WPI Section Ch Week 198903, Derwent World Patents Index; Class B02, AN 1989-019684, XP002295579 [A] 1,2,6 * abstract * | [Y] AMON U ET AL: "CGP 41251, a novel protein kinase inhibitor with in vitro selectivity for protein kinase C, strongly inhibits immunological activation of human skin mast cells and human basophils.", PHARMACOLOGY. SEP 1993, vol. 47, no. 3, September 1993 (1993-09-01), pages 200 - 208, XP009036185, ISSN: 0031-7012 [Y] 1-3,6,8,10,11,13-19 * See abstract * * page 202, column 2, line LAST - page 203, column 1 * * page 207, column 2 * DOI: http://dx.doi.org/10.1159/000139098 | [Y] KUROSAWA M ET AL: "Effect of staurosporine on histamine release from rat serosal mast cells.", ANNALS OF ALLERGY. SEP 1989, vol. 63, no. 3, September 1989 (1989-09-01), pages 231 - 234, XP009036192, ISSN: 0003-4738 [Y] 1-3,6,8,10,11,13-19 * the whole document * | [T] OPDAL S H ET AL: "New insight into sudden infant-death syndrome", LANCET THE, LANCET LIMITED. LONDON, GB, vol. 364, no. 9437, 4 September 2004 (2004-09-04), pages 825 - 826, XP004552551, ISSN: 0140-6736 [T] 1-3,6,8,11,19 * the whole document * DOI: http://dx.doi.org/10.1016/S0140-6736(04)16998-5 | [A] WARK P A ET AL: "Allergic bronchopulmonary aspergillosis: new concepts of pathogenesis and treatment.", RESPIROLOGY (CARLTON, VIC.) MAR 2001, vol. 6, no. 1, March 2001 (2001-03-01), pages 1 - 7, XP002313470, ISSN: 1323-7799 [A] 1-3,6,8,10,11,13-19 * abstract * * table 2 * * See page 4 "Management of allergic bronchopulmonary aspergillosis". * * page 4, column 1 - page 5, column 2 * * page 6, column 1 * DOI: http://dx.doi.org/10.1046/j.1440-1843.2001.00289.x | [A] GREENBERGER PAUL A: "Clinical aspects of allergic bronchopulmonary aspergillosis.", FRONTIERS IN BIOSCIENCE : A JOURNAL AND VIRTUAL LIBRARY. 1 JAN 2003, vol. 8, 1 January 2003 (2003-01-01), pages s119 - s127, XP002313471, ISSN: 1093-4715 [A] 1-3,6,8,10,11,13-19 * See page 125: "Approach to treatment of allergic bronchopulmonary aspergillosis" * | [A] SVIRSHCHEVSKAYA E V ET AL: "Immunotherapy of allergic bronchopulmonary aspergillosis: a clinical and experimental approach.", FRONTIERS IN BIOSCIENCE : A JOURNAL AND VIRTUAL LIBRARY. 1 JAN 2003, vol. 8, 1 January 2003 (2003-01-01), pages s92 - 101, XP002313472, ISSN: 1093-4715 [A] 1-3,6,8,10,11,13-19 * abstract * | [A] BRADSHAW D ET AL: "THERAPEUTIC POTENTIAL OF PROTEIN KINASE C INHIBITORS", AGENTS AND ACTIONS, BIRKHAEUSER VERLAG, BASEL, CH, vol. 38, 1993, pages 135 - 147, XP009034964, ISSN: 0065-4299 [A] 1-3,6,8,10,11,13-19 * abstract * * See page 138, columns 1,2: "Multiple sclerosis" * * See page 142, column 1: reference to staurosporine * * table 1 * DOI: http://dx.doi.org/10.1007/BF02027225 | [A] HUDSON S J ET AL: "Intracellular signaling of tumor necrosis factor-alpha in brain microvascular endothelial cells is mediated by a protein tyrosine kinase and protein kinase C-dependent pathway.", JOURNAL OF NEUROIMMUNOLOGY. NOV 1996, vol. 70, no. 2, November 1996 (1996-11-01), pages 199 - 206, XP002313473, ISSN: 0165-5728 [A] 1-3,6,8,10,11,13-19 * See page 201, column 2 - page 202, column 2, "Results; pages 204-205, "discussion"; figure 3C; and in particular the references to staurosporin * DOI: http://dx.doi.org/10.1016/S0165-5728(96)00116-6 | [A] JUREWICZ A M ET AL: "Shedding of TNF receptors in multiple sclerosis patients.", NEUROLOGY. 22 OCT 1999, vol. 53, no. 7, 22 October 1999 (1999-10-22), pages 1409 - 1414, XP008041519, ISSN: 0028-3878 [A] 1-3,6,8,10,11,13-19 * See page 1412, second column: "Protein kinase C inhibition" * * figure 6 * | [E] DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; MORISHITA, TSUYOSHI ET AL: "Drug for nerve regeneration containing glycogen synthase kinase-3 inhibitors", XP002313532, retrieved from STN Database accession no. 2004:902218 [E] 1-3,6,8,10,11,13-19 * abstract * | [E] DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; KITA, YASUHIRO ET AL: "Remedy for cerebral neurodegenerative diseases using PPAR.delta. agonist", XP002313533, retrieved from STN Database accession no. 2004:927076 [E] 1-3,6,8,10,11,13-19 * abstract * | [A] LONGLEY B J ET AL: "NEW APPROACHES TO THERAPY FOR MASTOCYTOSIS A CASE FOR TREATMENT WITH KIT KINASE INHIBITORS", HEMATOLOGY - ONCOLOGY CLINICS OF NORTH AMERICA, W.B. SAUNDERS, US, vol. 14, no. 3, June 2000 (2000-06-01), pages 689 - 695, XP008010967, ISSN: 0889-8588 [A] 1-19 * the whole document * DOI: http://dx.doi.org/10.1016/S0889-8588(05)70302-6 | [A] THARP M D: "Mastocytosis", CURRENT PROBLEMS IN DERMATOLOGY 1998 UNITED STATES, vol. 10, no. 5, 1998, pages 181 - 210, XP009030211, ISSN: 1040-0486 [A] 1-19 * See pages 202-205: " management" * DOI: http://dx.doi.org/10.1016/S1040-0486(98)90006-0 | [Y] MAHBOOBI S ET AL: "Homoarcyriaflavin: Synthesis of ring-expanded arcyriaflavin analogues", JOURNAL OF ORGANIC CHEMISTRY 19991029 US, vol. 64, no. 22, 29 October 1999 (1999-10-29), pages 8130 - 8137, XP002482188, ISSN: 0022-3263 [Y] 1,4-7,19 * See scheme 3: compounds 22-25 (falling under formula B) * DOI: http://dx.doi.org/10.1021/jo981926g | [Y] MERRITT J E ET AL: "The bisindolylmaleimide protein kinase C inhibitor, Ro 32-2241, reverses multidrug resistance in KB tumour cells.", CANCER CHEMOTHERAPY AND PHARMACOLOGY 1999, vol. 43, no. 5, 1999, pages 371 - 378, XP002482189, ISSN: 0344-5704 [Y] 1,4-7,19 * See figure 1: Ro 32-2241 * * See abstract, and page 375: effect of Ro 32-2241 on sensitivity of KB cells to chemotherapic agents and see page 376 ff: discussion * DOI: http://dx.doi.org/10.1007/s002800050909 | [Y] COOLS JAN ET AL: "PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRalpha-induced myeloproliferative disease.", CANCER CELL MAY 2003, vol. 3, no. 5, May 2003 (2003-05-01), pages 459 - 469, XP002482190, ISSN: 1535-6108 [Y] 1-19 * the whole document * DOI: http://dx.doi.org/10.1016/S1535-6108(03)00108-9 | [PXY] GOTLIB JASON ET AL: "PKC412, inhibitor of the KIT tyrosine kinase, demonstrates efficacy in mast cell leukemia with the D816V KIT mutation.", BLOOD, vol. 102, no. 11, 16 November 2003 (2003-11-16), & 45TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY; SAN DIEGO, CA, USA; DECEMBER 06-09, 2003, pages 919a, XP001194849, ISSN: 0006-4971 [PX] 1-19 * abstract * [Y] 1-19 DOI: http://dx.doi.org/10.1182/blood-2002-11-3391 | International search | [X] WO9749406 (CEPHALON INC et al.) [X] 1,2,6 * claims 2,5 * | [PX] WO03065995 (SUPERGEN INC et al.) [PX] 1,2,4,6 * claims 33,35,45,53 * | [X] WO9962537 (UNIV ROCKEFELLER et al.) [X] 1,2,6 * page 5, lines 7-9; claims 12,16,18,26 * | [A] WO9848795 (LILLY CO ELI et al.) [A] 1 * page 3, lines 21,22; claim - * | [A] JPS63295589 | [A] WO0246197 (ORTHO MCNEIL PHARM INC et al.) [A] 1 * claims 13-17,31,32 * | [A] EP0470490 (HOFFMANN LA ROCHE et al.) [A] 1,2 * page 6, line 55; claim 1 * | [X] WO03037347 (NOVARTIS AG et al.) [X] 10 * claim - * | [A] WO02080925 (NOVARTIS AG et al.) [A] 1-19 * See claim 1: treatment of infant death syndrome, bronchopulmonary aspergillosis, mastocytosis, multiple sclerosis.;; claims 4,5 * | [A] US4639455 (MOORE LUANA et al.) [A] 1-3,6,8,11,19 * See claim 1: prevention of sudden infant death syndrome * | [A] EP0518468 (NEURIM PHARMA 1991 et al.) [A] 1-3,6,8,11,19 * claim 6 * * See claim 6: prevention of sudden infant death syndrome. * | [A] WO9631514 (SANDOZ LTD et al.) [A] 1-3,6,8,10,11,13-19 * See treatment of bronchopulmonary aspergillosis: page 15, line 6;; claim 1 * | [E] WO2004091663 (KYOWA HAKKO KOGYO KK et al.) | [E] WO2004093910 (FUJISAWA PHARMACEUTICAL CO et al.) | [A] DATABASE WPI Section Ch Week 198903, Derwent World Patents Index; Class B02, AN 1989-019684, XP002295579 [A] 1,2,6 * abstract * | [Y] AMON U ET AL: "CGP 41251, a novel protein kinase inhibitor with in vitro selectivity for protein kinase C, strongly inhibits immunological activation of human skin mast cells and human basophils.", PHARMACOLOGY. SEP 1993, vol. 47, no. 3, September 1993 (1993-09-01), pages 200 - 208, XP009036185, ISSN: 0031-7012 [Y] 1-3,6,8,10,11,13-19 * See abstract * * page 202, column 2, line LAST - page 203, column 1 * * page 207, column 2 * DOI: http://dx.doi.org/10.1159/000139098 | [Y] KUROSAWA M ET AL: "Effect of staurosporine on histamine release from rat serosal mast cells.", ANNALS OF ALLERGY. SEP 1989, vol. 63, no. 3, September 1989 (1989-09-01), pages 231 - 234, XP009036192, ISSN: 0003-4738 [Y] 1-3,6,8,10,11,13-19 * the whole document * | [T] OPDAL S H ET AL: "New insight into sudden infant-death syndrome", LANCET THE, LANCET LIMITED. LONDON, GB, vol. 364, no. 9437, 4 September 2004 (2004-09-04), pages 825 - 826, XP004552551, ISSN: 0140-6736 [T] 1-3,6,8,11,19 * the whole document * DOI: http://dx.doi.org/10.1016/S0140-6736(04)16998-5 | [A] WARK P A ET AL: "Allergic bronchopulmonary aspergillosis: new concepts of pathogenesis and treatment.", RESPIROLOGY (CARLTON, VIC.) MAR 2001, vol. 6, no. 1, March 2001 (2001-03-01), pages 1 - 7, XP002313470, ISSN: 1323-7799 [A] 1-3,6,8,10,11,13-19 * abstract * * table 2 * * See page 4 "Management of allergic bronchopulmonary aspergillosis". * * page 4, column 1 - page 5, column 2 * * page 6, column 1 * DOI: http://dx.doi.org/10.1046/j.1440-1843.2001.00289.x | [A] GREENBERGER PAUL A: "Clinical aspects of allergic bronchopulmonary aspergillosis.", FRONTIERS IN BIOSCIENCE : A JOURNAL AND VIRTUAL LIBRARY. 1 JAN 2003, vol. 8, 1 January 2003 (2003-01-01), pages s119 - s127, XP002313471, ISSN: 1093-4715 [A] 1-3,6,8,10,11,13-19 * See page 125: "Approach to treatment of allergic bronchopulmonary aspergillosis" * | [A] SVIRSHCHEVSKAYA E V ET AL: "Immunotherapy of allergic bronchopulmonary aspergillosis: a clinical and experimental approach.", FRONTIERS IN BIOSCIENCE : A JOURNAL AND VIRTUAL LIBRARY. 1 JAN 2003, vol. 8, 1 January 2003 (2003-01-01), pages s92 - 101, XP002313472, ISSN: 1093-4715 [A] 1-3,6,8,10,11,13-19 * abstract * | [A] BRADSHAW D ET AL: "THERAPEUTIC POTENTIAL OF PROTEIN KINASE C INHIBITORS", AGENTS AND ACTIONS, BIRKHAEUSER VERLAG, BASEL, CH, vol. 38, 1993, pages 135 - 147, XP009034964, ISSN: 0065-4299 [A] 1-3,6,8,10,11,13-19 * abstract * * See page 138, columns 1,2: "Multiple sclerosis" * * See page 142, column 1: reference to staurosporine * * table 1 * DOI: http://dx.doi.org/10.1007/BF02027225 | [A] HUDSON S J ET AL: "Intracellular signaling of tumor necrosis factor-alpha in brain microvascular endothelial cells is mediated by a protein tyrosine kinase and protein kinase C-dependent pathway.", JOURNAL OF NEUROIMMUNOLOGY. NOV 1996, vol. 70, no. 2, November 1996 (1996-11-01), pages 199 - 206, XP002313473, ISSN: 0165-5728 [A] 1-3,6,8,10,11,13-19 * See page 201, column 2 - page 202, column 2, "Results; pages 204-205, "discussion"; figure 3C; and in particular the references to staurosporin * DOI: http://dx.doi.org/10.1016/S0165-5728(96)00116-6 | [A] JUREWICZ A M ET AL: "Shedding of TNF receptors in multiple sclerosis patients.", NEUROLOGY. 22 OCT 1999, vol. 53, no. 7, 22 October 1999 (1999-10-22), pages 1409 - 1414, XP008041519, ISSN: 0028-3878 [A] 1-3,6,8,10,11,13-19 * See page 1412, second column: "Protein kinase C inhibition" * * figure 6 * | [E] DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; MORISHITA, TSUYOSHI ET AL: "Drug for nerve regeneration containing glycogen synthase kinase-3 inhibitors", XP002313532, retrieved from STN Database accession no. 2004:902218 [E] 1-3,6,8,10,11,13-19 * abstract * | [E] DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; KITA, YASUHIRO ET AL: "Remedy for cerebral neurodegenerative diseases using PPAR.delta. agonist", XP002313533, retrieved from STN Database accession no. 2004:927076 [E] 1-3,6,8,10,11,13-19 * abstract * | [A] LONGLEY B J ET AL: "NEW APPROACHES TO THERAPY FOR MASTOCYTOSIS A CASE FOR TREATMENT WITH KIT KINASE INHIBITORS", HEMATOLOGY - ONCOLOGY CLINICS OF NORTH AMERICA, W.B. SAUNDERS, US, vol. 14, no. 3, June 2000 (2000-06-01), pages 689 - 695, XP008010967, ISSN: 0889-8588 [A] 1-19 * the whole document * DOI: http://dx.doi.org/10.1016/S0889-8588(05)70302-6 | [A] THARP M D: "Mastocytosis", CURRENT PROBLEMS IN DERMATOLOGY 1998 UNITED STATES, vol. 10, no. 5, 1998, pages 181 - 210, XP009030211, ISSN: 1040-0486 [A] 1-19 * See pages 202-205: " management" * DOI: http://dx.doi.org/10.1016/S1040-0486(98)90006-0 |